{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:33:44Z","timestamp":1759667624340,"version":"3.30.2"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Our team recently published outcomes of a novel technique for the administration of Collagenase Clostridium histolyticum (CCH), which resulted in improved curvature outcomes and reduced number of CCH injections required.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To provide a detailed and illustrated description of our CCH-administration technique.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A descriptive summary is provided of the technique, including drug administration, protocol modifications, and post-treatment protocols. Additional details are provided on measurement techniques and disease classification.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>Key outcomes include a written and illustrated description of the injection technique and pre-, and postinjection management.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The use of a modified CCH-administration technique has previously been shown to result in mean improvements of 54%\u201358% in penile curvature while significantly reducing the total number of injections applied. These findings represent the largest improvements published to date. Key aspects of the technique include back-to-back day administration of 0.9\u00a0mg suspended in 0.8\u00a0mL, application to an ~3\u2009\u00d7\u20091 cm region, inclusion of the dorsal septum (exempting ventral curves), administration during a full erection (day 1), repeat artificial erections with the first injection of each series, in-office modeling (day 2), and post-treatment use of PDE5s and Restorex traction. Appropriate patient counseling on expectations and necessity of complying with all treatment protocols (including post-treatment wrapping) is critical to optimizing outcomes. Common side effects may include ecchymoses, hematomas, blood blisters, impacts on erections and penile sensation, bronzing of the skin, and skin scarring, while more severe complications are rare (&amp;lt;1%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>The current manuscript provides a more detailed description of previously published techniques to aid providers in implementation and to mitigate potential adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>Strengths include reliance on the largest single-team series published on CCH outcomes, rigorous study methodology, prospective\/sequential series, and step-wise improvements. Limitations include data obtained from a single center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The current manuscript provides a detailed narrative and illustrated description of our current CCH-administration technique.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdae134","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T10:30:24Z","timestamp":1734172224000},"page":"1169-1177","source":"Crossref","is-referenced-by-count":1,"title":["An illustrated description of a modified collagenase <i>Clostridium histolyticum<\/i> protocol for Peyronie\u2019s disease"],"prefix":"10.1093","volume":"21","author":[{"given":"Landon","family":"Trost","sequence":"first","affiliation":[{"name":"Department of Life Sciences, Brigham Young University , Provo, UT, 84602,","place":["United States"]},{"name":"Male Fertility and Peyronie\u2019s Clinic , Orem, UT, 84057,","place":["United States"]},{"name":"CURE PD , Orem, UT, 84057,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"issue":"2","key":"2024121410301761700_ref1","doi-asserted-by":"publisher","first-page":"100321","DOI":"10.1016\/j.esxm.2021.100321","article-title":"Treatment patterns and healthcare outcomes with collagenase Clostridium histolyticum vs surgery in Peyronie's disease: a retrospective claims database analysis","volume":"9","author":"Trost","year":"2021","journal-title":"Sex Med"},{"issue":"1","key":"2024121410301761700_ref2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"issue":"1","key":"2024121410301761700_ref3","doi-asserted-by":"publisher","first-page":"102526","DOI":"10.1016\/j.purol.2023.09.013","article-title":"New protocol in the treatment of Peyronie's disease by combining platelet-rich plasma, percutaneous needle tunneling, and penile modeling: preliminary results","volume":"34","author":"Alshuaibi","year":"2023","journal-title":"Prog Urol"},{"issue":"2","key":"2024121410301761700_ref4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jsxmed\/qdac030","article-title":"Multiple courses of intralesional collagenase injections for Peyronie disease: a retrospective analysis","volume":"20","author":"Li","year":"2023","journal-title":"J Sex Med"},{"issue":"1","key":"2024121410301761700_ref5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.euf.2022.09.019","article-title":"Collagenase Clostridium histolyticum treatment improves degree of curvature in Peyronie's disease with calcified plaques","volume":"9","author":"Masterson","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"1","key":"2024121410301761700_ref6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/bco2.185","article-title":"Improvement in the ability to have sex in patients with Peyronie's disease treated with collagenase Clostridium histolyticum","volume":"4","author":"Geelhoed","year":"2023","journal-title":"BJUI Compass"},{"issue":"11","key":"2024121410301761700_ref7","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.jsxm.2022.08.001","article-title":"Predictors of curvature improvement in men with Peyronie's disease treated with Intralesional collagenase Clostridium histolyticum","volume":"19","author":"Flores","year":"2022","journal-title":"J Sex Med"},{"issue":"8","key":"2024121410301761700_ref8","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.21037\/tau-22-188","article-title":"Intralesional collagenase Clostridium histolyticum for acute phase Peyronie's disease: a single-center, retrospective cohort study","volume":"11","author":"Hu","year":"2022","journal-title":"Transl Androl Urol"},{"issue":"5","key":"2024121410301761700_ref9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4111\/icu.20220145","article-title":"Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie's disease: a prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates","volume":"63","author":"Chung","year":"2022","journal-title":"Investig Clin Urol"},{"issue":"3","key":"2024121410301761700_ref10","doi-asserted-by":"publisher","first-page":"100375","DOI":"10.1016\/j.esxm.2021.100375","article-title":"Safety and efficacy study of collagenase Clostridium histolyticum applied with an intensive protocol in the treatment of Peyronie's disease","volume":"9","author":"Melgarejo-Segura","year":"2021","journal-title":"Sex Med"},{"issue":"3","key":"2024121410301761700_ref11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.acuro.2020.06.016","article-title":"Efficacy and safety of collagenase Clostridium histolyticum in Peyronie's disease following a modified treatment protocol","volume":"45","author":"Garcia Cruz","year":"2021","journal-title":"Actas Urol Esp (Engl Ed)"},{"issue":"3","key":"2024121410301761700_ref12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41443-020-0292-y","article-title":"Treatment of peyronie's disease with combination of Clostridium histolyticum collagenase and penile traction therapy: a prospective, multicenter, single-arm study","volume":"33","author":"Garcia-Gomez","year":"2021","journal-title":"Int J Impot Res"},{"key":"2024121410301761700_ref13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.urology.2020.07.048","article-title":"Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute phase Peyronie's disease: a multi-institutional analysis","volume":"145","author":"Nguyen","year":"2020","journal-title":"Urology"},{"key":"2024121410301761700_ref14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.urology.2020.05.076","article-title":"Treatment-related outcomes for patients with atypical Peyronie's disease using Xiaflex injections","volume":"143","author":"El-Khatib","year":"2020","journal-title":"Urology"},{"issue":"6","key":"2024121410301761700_ref15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40261-020-00916-4","article-title":"Efficacy of collagenase Clostridium histolyticum (Xiapex((R))) in patients with the acute phase of Peyronie's disease","volume":"40","author":"Cocci","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2024121410301761700_ref16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.urology.2020.01.035","article-title":"The influence of indentation deformity on outcomes with Intralesional collagenase Clostridium histolyticum monotherapy for Peyronie's disease","volume":"139","author":"Ziegelmann","year":"2020","journal-title":"Urology"},{"key":"2024121410301761700_ref17","doi-asserted-by":"crossref","first-page":"e13527","DOI":"10.1111\/and.13527","article-title":"Second cycle of intralesional collagenase Clostridium histolyticum for Peyronie's disease using the modified shortened protocol: results from a retrospective analysis","volume":"52","author":"Capece","year":"2020","journal-title":"Andrologia"},{"key":"2024121410301761700_ref18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.urology.2017.01.054","article-title":"Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease","volume":"104","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"key":"2024121410301761700_ref19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.urology.2022.09.017","article-title":"Improved Peyronie's disease curvature outcomes using a novel collagenase administration protocol","volume":"170","author":"Flores","year":"2022","journal-title":"Urology"},{"key":"2024121410301761700_ref20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.urology.2017.04.045","article-title":"Self-reported clinical meaningfulness early in the treatment course predicts objective outcomes in men undergoing collagenase Clostridium histolyticum injections for Peyronie disease","volume":"106","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"issue":"4","key":"2024121410301761700_ref21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/JU.0000000000000032","article-title":"Intralesional collagenase Clostridium histolyticum causes meaningful improvement in men with Peyronie's disease: results of a multi-institutional analysis","volume":"201","author":"Hellstrom","year":"2019","journal-title":"J Urol"},{"issue":"4 Part 1","key":"2024121410301761700_ref22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","article-title":"Restoration of penile function and patient satisfaction with Intralesional collagenase Clostridium histolyticum injection for Peyronie's disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J Urol"},{"key":"2024121410301761700_ref23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","article-title":"Plaque calcification: an important predictor of collagenase Clostridium histolyticum treatment outcomes for men with Peyronie's disease","volume":"119","author":"Wymer","year":"2018","journal-title":"Urology"},{"issue":"2","key":"2024121410301761700_ref24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.sxmr.2016.07.004","article-title":"Review of management options for patients with atypical Peyronie's disease","volume":"5","author":"Yafi","year":"2017","journal-title":"Sex Med Rev"},{"key":"2024121410301761700_ref25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.urology.2019.01.055","article-title":"Safety and efficacy of collagenase Clostridium histolyticum in Peyronie's disease men with ventral curvatures","volume":"129","author":"Alom","year":"2019","journal-title":"Urology"},{"issue":"2","key":"2024121410301761700_ref26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/jsxmed\/qdac006","article-title":"Efficacy of collagenase Clostridium histolyticum in men with congenital penile curvature","volume":"20","author":"Kulkarni","year":"2023","journal-title":"J Sex Med"},{"issue":"6","key":"2024121410301761700_ref27","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jsxm.2019.03.007","article-title":"Efficacy of combined collagenase Clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie's disease","volume":"16","author":"Alom","year":"2019","journal-title":"J Sex Med"},{"key":"2024121410301761700_ref28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.urology.2023.11.024","article-title":"Changes in point of maximal curvature during collagenase Clostridium histolyticum injections for Peyronie's disease","volume":"184","author":"Larson","year":"2023","journal-title":"Urology"},{"issue":"10","key":"2024121410301761700_ref29","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jsxm.2018.08.012","article-title":"Sildenafil 25 mg ODT + collagenase clostridium hystoliticum vs collagenase clostridium hystoliticum alone for the Management of Peyronie's disease: a matched-pair comparison analysis","volume":"15","author":"Cocci","year":"2018","journal-title":"J Sex Med"},{"issue":"5","key":"2024121410301761700_ref30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/JU.0000000000003634","article-title":"Comparison of collagenase Clostridium histolyticum to surgery for the Management of Peyronie's disease: a randomized trial","volume":"210","author":"Green","year":"2023","journal-title":"J Urol"},{"issue":"6","key":"2024121410301761700_ref31","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jsxm.2021.03.075","article-title":"Continuing collagenase Clostridium histolyticum injections among initial nonresponders results in significant curvature improvements in the majority of Peyronie's disease men","volume":"18","author":"Alom","year":"2021","journal-title":"J Sex Med"},{"issue":"3","key":"2024121410301761700_ref32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/sxmrev\/qeae004","article-title":"Collagenase Clostridium histolyticum for Peyronie's disease: a contemporary atlas of complications and their management","volume":"12","author":"Furtado","year":"2024","journal-title":"Sex Med Rev"},{"issue":"1","key":"2024121410301761700_ref33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12894-021-00858-9","article-title":"Lateral herniation during treatment with collagenase Clostridium histolyticum (Xiaflex) for Peyronie's disease","volume":"21","author":"Gannon","year":"2021","journal-title":"BMC Urol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/12\/1169\/60927291\/qdae134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/12\/1169\/60927291\/qdae134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T10:30:26Z","timestamp":1734172226000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/21\/12\/1169\/7914356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,3]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdae134","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"type":"print","value":"1743-6095"},{"type":"electronic","value":"1743-6109"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,12,1]]}}}